ArticleElectrophoresis2026
Glycosylation Signatures of Thyroglobulin in Papillary Thyroid Carcinoma.
Article in Electrophoresis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Thyroglobulin (Tg) is a clinically established biomarker for thyroid cancer; however, its diagnostic specificity remains limited due to confounding benign conditions. This study investigated changes in the site-specific N-glycosylation profiles of thyroglobulin protein derived from papillary thyroid cancer and adjacent healthy tissues. Using a bottom-up mass spectrometry-based glycoproteomic approach, we analyzed site-specific glycan compositions in retrospective patient tissue samples. Nine distinct N-glycosylation sites were identified and quantified in this study. Statistical analysis revealed significant differences in the site-specific glycosylation profiles. The glycan compositions HexNAc(3)Hex(5) and HexNAc(3)Hex(6) at the Asn1365 site exhibited a discriminatory potential. Dimensionality reduction and hierarchical clustering based on the top four glycopeptide variants showed observable grouping of tumor versus normal samples. Furthermore, supervised machine learning models were used to evaluate these features, with a neural network achieving the highest diagnostic performance (area under the curve [AUC] = 0.83). Feature importance analysis indicated that Asn1365-HexNAc(3)Hex(6) was the strongest contributor to the predictive power of the model. The observed alterations in specific glycan compositions, combined with machine learning evaluations, may offer improved diagnostic specificity and provide promising avenues for personalized thyroid cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.